[go: up one dir, main page]

AU2712899A - Glp-2 derivatives with helix-content exceeding 25 percent, forming partially structured micellar-like aggregates - Google Patents

Glp-2 derivatives with helix-content exceeding 25 percent, forming partially structured micellar-like aggregates

Info

Publication number
AU2712899A
AU2712899A AU27128/99A AU2712899A AU2712899A AU 2712899 A AU2712899 A AU 2712899A AU 27128/99 A AU27128/99 A AU 27128/99A AU 2712899 A AU2712899 A AU 2712899A AU 2712899 A AU2712899 A AU 2712899A
Authority
AU
Australia
Prior art keywords
glp
helix
aggregates
percent
derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU27128/99A
Inventor
Soren Erik Bjorn
Per Olaf Huusfeldt
Niels C. Kaarsholm
Liselotte Bjerre Knudsen
Per Franklin Nielsen
Helle Birk Olsen
Lars Thim
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk AS
Original Assignee
Novo Nordisk AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk AS filed Critical Novo Nordisk AS
Publication of AU2712899A publication Critical patent/AU2712899A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
AU27128/99A 1998-02-27 1999-02-25 Glp-2 derivatives with helix-content exceeding 25 percent, forming partially structured micellar-like aggregates Abandoned AU2712899A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DK27198 1998-02-27
DK271/98 1998-02-27
PCT/DK1999/000080 WO1999043361A1 (en) 1998-02-27 1999-02-25 Glp-2 derivatives with helix-content exceeding 25 %, forming partially structured micellar-like aggregates

Publications (1)

Publication Number Publication Date
AU2712899A true AU2712899A (en) 1999-09-15

Family

ID=8091669

Family Applications (1)

Application Number Title Priority Date Filing Date
AU27128/99A Abandoned AU2712899A (en) 1998-02-27 1999-02-25 Glp-2 derivatives with helix-content exceeding 25 percent, forming partially structured micellar-like aggregates

Country Status (4)

Country Link
EP (1) EP1060192A2 (en)
JP (1) JP2002504527A (en)
AU (1) AU2712899A (en)
WO (1) WO1999043361A1 (en)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9930882D0 (en) 1999-12-30 2000-02-23 Nps Allelix Corp GLP-2 formulations
US7371721B2 (en) 2000-09-18 2008-05-13 Sanos Bioscience A/S Use of GLP-2 and related compounds for the treatment, prevention, diagnosis, and prognosis of bone-related disorders and calcium homeostasis related syndromes
JP5161412B2 (en) 2000-09-18 2013-03-13 サノス・バイオサイエンス・アクティーゼルスカブ Methods of using GLP-1 and GLP-2 peptides
EP1360202B1 (en) * 2001-02-16 2008-05-21 ConjuChem Biotechnologies Inc. Long lasting glucagon-like peptide 2 (glp-2) for the treatment of gastrointestinal diseases and disorders
WO2004035624A2 (en) * 2002-10-14 2004-04-29 Novo Nordisk A/S Glucagon - like peptide - 2 variants
BRPI0408978B8 (en) 2003-04-08 2021-07-27 Novo Nordisk As processes for regenerating a chromatographic stationary phase
WO2004089985A1 (en) * 2003-04-11 2004-10-21 Novo Nordisk A/S Stable pharmaceutical compositions
ES2375056T3 (en) 2003-06-03 2012-02-24 Novo Nordisk A/S PEPT� COMPOSITIONS STABILIZED PHARMACEUTICAL DICAS
KR101308912B1 (en) 2003-06-03 2013-09-23 노보 노르디스크 에이/에스 Stabilized pharmaceutical peptide compositions
RU2401276C2 (en) * 2003-09-19 2010-10-10 Ново Нордиск А/С Glucagon-like peptide-1 (glp-1) derivatives
JP2007537981A (en) * 2003-09-19 2007-12-27 ノボ　ノルディスク　アクティーゼルスカブ Novel plasma protein affinity tag
WO2005027978A2 (en) 2003-09-19 2005-03-31 Novo Nordisk A/S Albumin-binding derivatives of therapeutic peptides
CN100444898C (en) * 2003-09-19 2008-12-24 诺沃挪第克公司 Albumin-binding derivatives of therapeutic peptides
ES2427150T3 (en) 2004-11-01 2013-10-29 Nps Pharmaceuticals, Inc. Treatment of patients with short bowel syndrome with colon in continuity
WO2006097535A2 (en) * 2005-03-18 2006-09-21 Novo Nordisk A/S Peptide agonists of the glucagon family with secretin like activity
BRPI0608516A2 (en) 2005-03-18 2010-11-16 Novo Nordisk As glp-1 analog, method for increasing the time of action in a patient of a glp-1 analog, pharmaceutical composition, and use of a compound
TWI372629B (en) 2005-03-18 2012-09-21 Novo Nordisk As Acylated glp-1 compounds
CN100418983C (en) * 2005-05-11 2008-09-17 中国药科大学 Human glucagon related peptide-2 analog
CN102027005A (en) 2008-05-15 2011-04-20 诺沃-诺迪斯克有限公司 Purification of peptides prepared by solid phase synthesis
KR20110039348A (en) 2008-08-06 2011-04-15 노보 노르디스크 헬스 케어 악티엔게젤샤프트 Conjugated Proteins with Extended In Vivo Efficacy
WO2010084173A1 (en) 2009-01-22 2010-07-29 Novo Nordisk Health Care Ag Stable growth hormone compounds
WO2011015649A1 (en) 2009-08-06 2011-02-10 Novo Nordisk Health Care Ag Growth hormones with prolonged in-vivo efficacy
KR101813595B1 (en) 2010-01-22 2017-12-29 노보 노르디스크 헬스 케어 악티엔게젤샤프트 Growth hormones with prolonged in-vivo efficacy
US9211342B2 (en) 2010-01-22 2015-12-15 Novo Nordisk Healthcare Ag Stable growth hormone compounds resistant to proteolytic degradation
US11045523B2 (en) 2013-04-05 2021-06-29 Novo Nordisk Healthcare Ag Formulation of growth hormone albumin-binder conjugate
WO2019086559A1 (en) 2017-10-31 2019-05-09 Adocia Composition comprising a glp-2 receptor agonist and a co-polyamino acid carrying carboxylate charges and hydrophobic radicals
KR20210126088A (en) 2019-02-11 2021-10-19 옵코 바이오로직스 리미티드 long-acting GLP-2 analogues
US20240374690A1 (en) 2021-01-25 2024-11-14 Mylan Ireland Limited Pharmaceutical Peptide Compositions and Methods of Preparation Thereof
US20250332099A1 (en) * 2021-09-10 2025-10-30 Zealand Pharma A/S Process for formulating compositions comprising glucagon-like-peptide-2 (glp-2) analogues

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU217684B (en) * 1993-09-17 2000-03-28 Novo Nordisk A/S Acylated insulin derivatives and pharmaceutical compositions containing them and their preparation
US5990077A (en) * 1995-04-14 1999-11-23 1149336 Ontario Inc. Glucagon-like peptide-2 and its therapeutic use
JP4064460B2 (en) * 1996-03-01 2008-03-19 ノボ ノルディスク アクティーゼルスカブ Use of a pharmaceutical composition comprising an appetite suppressive peptide
EP2218734B1 (en) * 1996-04-12 2013-06-05 1149336 Ontario Inc. Glucagon-like peptide-2 analogs
WO1998008872A1 (en) * 1996-08-30 1998-03-05 Novo Nordisk A/S Glp-2 derivatives

Also Published As

Publication number Publication date
WO1999043361A8 (en) 1999-10-14
JP2002504527A (en) 2002-02-12
WO1999043361A1 (en) 1999-09-02
EP1060192A2 (en) 2000-12-20

Similar Documents

Publication Publication Date Title
AU2712899A (en) Glp-2 derivatives with helix-content exceeding 25 percent, forming partially structured micellar-like aggregates
AU2001230026A1 (en) 2,4-diaminothiazole derivatives
AU2001294606A1 (en) Substituted azepino(4,5b)indoline derivatives
PT1589017E (en) 12,13-modified epothilone derivatives
AU1444800A (en) Microscale patterning and articles formed thereby
AU2001244618A1 (en) Substituted 1,3-thiazole compounds, their production and use
AU6162398A (en) Polymer nanocomposite composition
AU4112497A (en) Glp-2 derivatives
AU6636598A (en) Novel 3,4-dialkoxyphenyl derivatives and the use thereof
AU3819200A (en) 2,4-diamino-pyrimidine derivatives
AU2507801A (en) Naphthopyrans with a heterocycle in the 5,6-position, preparation, and compositions and matrices containing them
AU3501800A (en) Aqueous dispersion composition and manufacturing method for the composition
AU2298200A (en) Stabilized filler, its production and use
EP1469001B8 (en) Corroles, including chiral derivatives and the use thereof
AU2001294240A1 (en) 2,2-diphenylbutanamide derivatives and medicines containing the same
AU6102599A (en) Melt-mouldable composites
AU5176299A (en) Compound, composition and use
AU2964899A (en) 2,4-dioxo-5-arylidenimino-1,3-pyrimidines
AU1896300A (en) Printing composition, process and printing device using the same
AU3880399A (en) Octahydropyrrolo-(3,4-c)carbazoles useful as analgesic agents
AU1513597A (en) 1,25-dihydroxy-16,22,23-trisdehydro-cholecalciferol derivatives
AU1127601A (en) Substituted nitrobenzene derivatives as medicines and other useful uses thereof
AU1223699A (en) Aluminium acetoacetate compounds, the production and use thereof as printing inkadditives
AU2818699A (en) Spinneret
AU2846099A (en) 1,3,4-thiadiazolylazo dyes and ink compositions containing the same

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase